This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1y4l

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1y4l.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1y4l.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1y4l| PDB=1y4l | SCENE= }}
{{STRUCTURE_1y4l| PDB=1y4l | SCENE= }}
-
'''Crystal structure of Bothrops asper myotoxin II complexed with the anti-trypanosomal drug suramin'''
+
===Crystal structure of Bothrops asper myotoxin II complexed with the anti-trypanosomal drug suramin===
-
==Overview==
+
<!--
-
Suramin, a synthetic polysulfonated compound, developed initially for the treatment of African trypanosomiasis and onchocerciasis, is currently used for the treatment of several medically relevant disorders. Suramin, heparin, and other polyanions inhibit the myotoxic activity of Lys49 phospholipase A2 analogues both in vitro and in vivo, and are thus of potential importance as therapeutic agents in the treatment of viperid snake bites. Due to its conformational flexibility around the single bonds that link the central phenyl rings to the secondary amide backbone, the symmetrical suramin molecule binds by an induced-fit mechanism complementing the hydrophobic surfaces of the dimer and adopts a novel conformation that lacks C2 symmetry in the dimeric crystal structure of the suramin-Bothrops asper myotoxin II complex. The simultaneous binding of suramin at the surfaces of the two monomers partially restricts access to the nominal active sites and significantly changes the overall charge of the interfacial recognition face of the protein, resulting in the inhibition of myotoxicity.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15961104}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15961104 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15961104}}
==About this Structure==
==About this Structure==
Line 33: Line 37:
[[Category: Anti-trypanosomal drug suramin]]
[[Category: Anti-trypanosomal drug suramin]]
[[Category: Bothrops asper myotoxin ii]]
[[Category: Bothrops asper myotoxin ii]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 15:52:13 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 03:39:36 2008''

Revision as of 00:39, 29 July 2008

Image:1y4l.png

Template:STRUCTURE 1y4l

Crystal structure of Bothrops asper myotoxin II complexed with the anti-trypanosomal drug suramin

Template:ABSTRACT PUBMED 15961104

About this Structure

1Y4L is a Single protein structure of sequence from Bothrops asper. Full crystallographic information is available from OCA.

Reference

Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin., Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Elias S, Tomaz MA, Lomonte B, Gutierrez JM, Arni RK, J Mol Biol. 2005 Jul 15;350(3):416-26. PMID:15961104

Page seeded by OCA on Tue Jul 29 03:39:36 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1y4l"
Personal tools